Yalaz K, Anlar B, Oktem F, Aysun S, Ustacelebi S, Gurcay O, Gucuyener K, Renda Y
Department of Pediatric Neurology, Hacettepe University, Ankara, Turkey.
Neurology. 1992 Mar;42(3 Pt 1):488-91. doi: 10.1212/wnl.42.3.488.
We treated 22 patients with subacute sclerosing panencephalitis (SSPE) with intraventricular alpha-interferon (IFN) and inosiplex PO and followed them for 2 to 54 months. Three deaths occurred. Clinical improvement, demonstrated by decreasing scores on the Neurological Disability Index, occurred in 11/22 (50%); five patients became stable, and the progression rate of the disease decreased in three. The remission rate was significantly higher than untreated controls from the same institution. Patients who had a slowly progressive disease responded best to treatment. Serious side effects were rare. We recommend intraventricular IFN, combined with oral inosiplex, in the treatment of SSPE.
